PENKA, Miroslav, Jiří SCHWARZ and Petra OVESNÁ. Léčba esenciální trombocytémie a dalších myeloproliferativních chorob anagrelidem (Anagrelid therapy of essential thrombocythemia and other myoproliferative disorders). Brno: Masarykova univerzita, 2016, 150 pp.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Léčba esenciální trombocytémie a dalších myeloproliferativních chorob anagrelidem
Name (in English) Anagrelid therapy of essential thrombocythemia and other myoproliferative disorders
Authors PENKA, Miroslav (203 Czech Republic, belonging to the institution), Jiří SCHWARZ (203 Czech Republic) and Petra OVESNÁ (203 Czech Republic, belonging to the institution).
Edition Brno, 150 pp. 2016.
Publisher Masarykova univerzita
Other information
Original language Czech
Type of outcome Research report
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/16:00094117
Organization unit Faculty of Medicine
Keywords in English thromboreductin; anagrelid; haematology
Changed by Changed by: Mgr. Jakub Gregor, Ph.D., učo 16577. Changed: 12/4/2017 09:22.
Abstract
Zpráva je komplexní analýzou registru českých pacientů léčených Thromboreductinem, která byla provedena na začátku roku 2016 na souboru 1 772 pacientů.
Abstract (in English)
The report is a comprehensive analysis of the Czech registry of patients treated with Thromboreductin. The analysis was performed in early 2016 with a cohort of 1,772 patients.
PrintDisplayed: 31/5/2024 22:42